|
|
1P7 |
|
Vaxjo ID |
372 |
|
Vaccine Adjuvant Name |
1P7 |
|
Description |
CCR5 natural adjuvant derived from CCL5 chemokine that induces Th1 response |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
CTA1-3M2e-DD (carrying three copies of M2e; amino acid sequence: SLLTEVETPIRNEWGSRSNDSSD) |
|
Function |
promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity |
| References |
Eliasson et al., 2008: Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008; 26(9); 1243-1252. [PubMed: 18243429].
|
|
